Auna Reiterates FY26 Revenue Guidance but Offers No Margin Relief

What happened

Auna issued a preliminary update to its full-year 2026 outlook on October 22, 2026, reaffirming that revenue growth should land in line with the 10–14% FX-neutral guidance communicated earlier in the year. The announcement follows the release of third-quarter operating KPIs showing higher surgeries, utilization, and oncology volumes, but it does not provide new detail on margins or leverage. Management had previously indicated that adjusted EBITDA growth would likely track toward the low end of that revenue range, excluding non-recurring Peru billing penalties, and this update appears to confirm that cautious stance. The core question remains whether rising volumes can convert into EBITDA, especially in Mexico where segment EBITDA was still down year over year in the second quarter. With full third-quarter results due on November 18, this update offers no incremental evidence to resolve the margin debate, leaving the stock's risk-reward unchanged at current levels.

Implication

The reaffirmation of top-line guidance provides modest comfort but fails to address the central issue of weak EBITDA conversion, particularly in Mexico and Peru. Until Auna demonstrates that higher utilization translates into segment profit improvement—Mexico EBITDA turning positive year over year and Peru billing penalties disappearing—the stock is unlikely to re-rate meaningfully. The current valuation at 5.4x EV/EBITDA is not attractive enough to compensate for a balance sheet with 3.6x leverage and 1.4x interest coverage. Price action since the second-quarter report has been rangebound, and this update gives no reason to expect a breakout. We maintain a neutral stance: consider adding only on a pullback toward $4.60 or on clear evidence of margin inflection, and trim above $6.40.

Thesis delta

The thesis delta is neutral: the preliminary outlook reiteration matches the existing base case of ~12% revenue growth with EBITDA at the low end of guidance. It does not introduce new information that would shift scenario probabilities or the WAIT rating. The key validation points—Mexico EBITDA inflection and Peru billing normalization—remain outstanding and are scheduled for the Q3 report on November 18.